

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-10. (Canceled)

11. (Currently Amended) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

a) a polypeptide sequence comprising SEQ ID NO:475; and
b) polypeptides having at least 90% identity to the full length of the polypeptide set forth in SEQ ID NO:475, wherein said polypeptides having at least 90% identity are immunologically reactive with an antibody and/or T cell that reacts with the polypeptide set forth in SEQ ID NO:475.

12. (Previously Presented) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polypeptide comprising at least 20 contiguous amino acids of the polypeptide set forth in SEQ ID NO:475, wherein said polypeptide comprising at least 20 contiguous amino acids is immunologically reactive with an antibody and/or T cell that reacts with the polypeptide set forth in SEQ ID NO:475.

13. (Currently Amended) The method of claim 11 or 12 wherein said immunostimulant is selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, and a saponin, alone or in combination MPL®, QS21, QS7,

Application No. 10/076,622
Reply to Advisory Action dated November 17, 2003

~~Esein, Digitonin, Quil A, and a combination of monophosphoryl lipid A together with an aluminum salt.~~